-
Innovation Ranking
NewInnovation Ranking – Dr. Reddy’s Laboratories Ltd
Dr. Reddy's Laboratories Ltd (Dr. Reddy's) is a pharmaceutical company that manufactures and markets generic formulations, active pharmaceutical ingredients (APIs), biosimilars and proprietary products. The company’s generic products are indicated for the treatment of gastrointestinal disorders, various cancer types, cardiovascular diseases, pain, central nervous system disorders, infectious diseases, and pediatric diseases. The company also develops and markets generic biosimilar products. Its pipeline includes New Chemical Entities (NCEs) that focus on the treatment of metabolic disorders, bacterial infections, pain, and inflammation....
-
Innovation Ranking
NewInnovation Ranking – Keurig Dr Pepper Inc
Keurig Dr Pepper Inc (KDP) is a manufacturer and distributor of non-alcoholic beverages. The company’s product portfolio includes coffees, carbonated soft drinks, ready-to-drink tea, water, juices, juice drinks and mixers, among others. KDP markets its products under brands such as Dr Pepper, Snapple, Keurig, Green Mountain, Donut Shop, Van Houtte, REVV, and Mott's. The company serves various bottlers, distributors, and retailers, including hypermarkets, supermarkets, mass merchandisers, e-commerce retailers, club stores, office superstores, fountains, vending machines, convenience stores, grocery and drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Crofelemer DR in Cholera
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crofelemer DR in Cholera report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Crofelemer DR in Cholera Drug Details: Crofelemer (Fulyzaq, Mytesi) is an anti...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crofelemer DR in Irritable Bowel Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crofelemer DR in Irritable Bowel Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Crofelemer DR in Irritable Bowel Syndrome Drug Details: Crofelemer (Fulyzaq,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DR-0201 in Hematological Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DR-0201 in Hematological Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DR-0201 in Hematological Tumor Drug Details: DR-0201 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rifaximin DR in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rifaximin DR in Sickle Cell Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rifaximin DR in Sickle Cell Disease Drug Details: Rifaximin delayed-release...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DR-0201 in Follicular Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DR-0201 in Follicular Lymphoma Drug Details: DR-0201 is under development for the treatment of hematologic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DR-0201 in Mantle Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DR-0201 in Mantle Cell Lymphoma Drug Details: DR-0201 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DR-0201 in Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DR-0201 in Chronic Lymphocytic Leukemia (CLL) Drug Details: DR-0201 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DR-0201 in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DR-0201 in Diffuse Large B-Cell Lymphoma Drug Details: DR-0201 is under development for the treatment...